NICE Template July 2015 1

NHS Rotherham Clinical Commissioning Group Framework of NICE Guidance July 2015

Guideline Title Summary Implications & Completed Actions No Action

TA345 Naloxegol for treating opioid-induced Naloxegol (Moventig) is recommended as a possible treatment for This treatment is constipation people with opioid induced constipation that has had an inadequate available as an response to laxatives. option for opioid induced What does this mean for me? constipation when If you have opioid induced constipation, and your doctor thinks that all other naloxegol is the right treatment, you should be able to have the treatments have treatment on the NHS. not provided the desired response. Naloxegol should be available on the NHS within 3 months of the (NHS Rotherham guidance being issued. CCG laxative guidance for adults) TA346 Aflibercept for treating diabetic macular Aflibercept (Eylea) injections are recommended as a possible This drug will be oedema treatment for some people with sight problems caused by diabetic initiated and macular oedema, as explained below. prescribed in secondary/tertiary What does this mean for me? care. If you have diabetic macular oedema and the central retina of your eye is 400 micrometres thick or more before treatment, and your NHS Rotherham doctor thinks that aflibercept is the right treatment, you should be CCG will accept able to have the treatment on the NHS. the recharged costs as NICE Aflibercept injections should be available on the NHS within 3 guidance as months of the guidance being issued. excluded drugs – guidance. If you are already having aflibercept injections for diabetic macular oedema and the central retinal thickness was less than 400 micrometres when treatment started, you should be able to continue having them until you and your doctor decide it is the right time to stop.

TA347 Nintedanib for previously treated locally Nintedanib (Vargatef), given with a drug called docetaxel, is This drug will be advanced, metastatic, or locally recurrent recommended. It is a possible treatment for people with a certain initiated and

0a98030eb668388db31fc506f3b858f3.doc 1 NHS Rotherham Clinical Commissioning Group Framework of NICE Guidance July 2015

non-small-cell lung cancer type (adenocarcinoma) of locally advanced, metastatic or locally prescribed in recurrent non-small-cell lung cancer that has got worse after secondary/tertiary previous chemotherapy. care.

What does this mean for me? NHSE is the If you have locally advanced, metastatic or locally recurrent non- responsible small-cell lung cancer of adenocarcinoma histology, and your commissioner for doctor thinks that nintedanib (with docetaxel) is the right this drug, although treatment, you should be able to have the treatment on the NHS. it is not routinely commissioned and Nintedanib should be available on the NHS within 3 months of the requires IFRs guidance being issued.

TA348 Everolimus for preventing organ rejection in Everolimus (Certican) is not recommended for preventing organ liver transplantation rejection in people having a liver transplant.

What does this mean for me? If you are already taking everolimus for preventing organ rejection after a liver transplant, you should be able to continue taking it until you and your doctor decide it is the right time to stop.

TA349 Dexamethasone intravitreal implant for Dexamethasone intravitreal implant (Ozurdex) is recommended as This drug will be treating diabetic macular oedema a possible treatment for people with sight problems caused by initiated and diabetic macular oedema if: prescribed in secondary/tertiary •there is an artificial lens in the eye to be treated, and care. •their diabetic macular oedema has not improved with non-corticosteroid treatment, or such treatment is not suitable for NHS Rotherham them. CCG will accept What does this mean for me? the recharged If you have diabetic macular oedema and your doctor thinks that costs as NICE dexamethasone intravitreal implant is the right treatment, you guidance as should be able to have the treatment on the NHS. excluded drugs – guidance. Dexamethasone intravitreal implant should be available on the

NHS within 3 months of the guidance being issued.

If you are not eligible for treatment as described above, you should be able to continue having treatment with dexamethasone intravitreal implant until you and your doctor decide it is the right time to stop.

TA350 Secukinumab for treating moderate to Secukinumab (Cosentyx) is recommended as a possible This drug will be severe plaque psoriasis treatment for people with plaque psoriasis if: initiated and prescribed in •standard assessments show that their psoriasis is severe and is secondary/tertiary affecting their quality of life, and care. •their psoriasis has not improved with other treatments including ciclosporin, methotrexate and PUVA (psoralen and long-wave NHS Rotherham ultraviolet radiation), or they have had side effects with these CCG will accept treatments in the past or there is a reason why they cannot have the recharged them. costs as NICE Treatment with secukinumab should be stopped after 12 weeks if guidance as the psoriasis does not improve enough according to standard excluded drugs – measures. guidance. IFRs What does this mean for me? If you have plaque psoriasis and your doctor thinks that secukinumab is the right treatment, you should be able to have the treatment on the NHS. Secukinumab should be available on the NHS within 3 months of the guidance being issued.

If you are not eligible for treatment as described above, you should be able to continue taking secukinumab until you and your doctor decide it is the right time to stop.

TA351 Cangrelor for reducing atherothrombotic NICE is unable to make a recommendation about the use in the events in people undergoing percutaneous NHS of cangrelor for reducing atherothrombotic events in people coronary intervention or awaiting surgery undergoing percutaneous coronary intervention or awaiting

requiring interruption of anti-platelet therapy surgery requiring interruption of anti-platelet therapy because no (terminated appraisal) evidence submission was received from The Medicines Company

0a98030eb668388db31fc506f3b858f3.doc 4